Loading…
Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments
Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment. Cross-sectional study using a phone questionnaire targeting 452...
Saved in:
| Published in: | Journal of comparative effectiveness research 2017-07, Vol.6 (5), p.405-412 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383 |
| container_end_page | 412 |
| container_issue | 5 |
| container_start_page | 405 |
| container_title | Journal of comparative effectiveness research |
| container_volume | 6 |
| creator | Al-Hussain, Fawaz Al-Salloum, Noura Alazwary, Naael Saeedi, Jameelah Howaidi, Sara Daif, Abdulkader |
| description | Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment.
Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital.
From 235 patients, 149 used interferons, 58 used fingolimod and 28 used natalizumab. Depression scores were similar among all demographic and drug groups. Interferons versus fingolimod anxiety scores were significantly different (p = 0.035). Stress scores were within normal limits.
Mild anxiety was higher among interferon users, which could be due to injection anxiety reasons. |
| doi_str_mv | 10.2217/cer-2016-0087 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1918384176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1918384176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383</originalsourceid><addsrcrecordid>eNp1kMtLxDAQh4MoKurRq-TowWoebZoeZX3Cghc9hzSdSqQvM6m4_70pu3ozl8kk3_xgPkLOObsWgpc3DkImGFcZY7rcI8eC5SJTksv9vzsrjsgZ4gdLR-m8KsQhORJaVVWp2TGZ7mAKgOjH4Yra4dtD3KTaUIzLM0X4guCjB6R-oP3cRT91QNF1EEb0SCebPoeIdEY_vCfoA1y0dWLSIM5Ix2A7msJs7BfulBy0tkM429UT8vZw_7p6ytYvj8-r23XmZC5j1ui6UE3V6sJVZd4wDjXTShXCigoUbxxzNWetVSBlDQ1LFrhwDKwTAExqeUIut7lTGD9nwGh6jw66zg4wzmh4xbXUOS9VQrMt6tJKGKA1U_C9DRvDmVk8m-TZLJ7N4jnxF7voue6h-aN_rSag2gLtHOek0SVDDsy2SxPe-QH-Cf8B9imPNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1918384176</pqid></control><display><type>article</type><title>Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments</title><source>PubMed Central</source><creator>Al-Hussain, Fawaz ; Al-Salloum, Noura ; Alazwary, Naael ; Saeedi, Jameelah ; Howaidi, Sara ; Daif, Abdulkader</creator><creatorcontrib>Al-Hussain, Fawaz ; Al-Salloum, Noura ; Alazwary, Naael ; Saeedi, Jameelah ; Howaidi, Sara ; Daif, Abdulkader</creatorcontrib><description>Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment.
Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital.
From 235 patients, 149 used interferons, 58 used fingolimod and 28 used natalizumab. Depression scores were similar among all demographic and drug groups. Interferons versus fingolimod anxiety scores were significantly different (p = 0.035). Stress scores were within normal limits.
Mild anxiety was higher among interferon users, which could be due to injection anxiety reasons.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer-2016-0087</identifier><identifier>PMID: 28699780</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Administration, Oral ; Adult ; anxiety ; Anxiety - etiology ; Cross-Sectional Studies ; DASS ; depression ; Depression - etiology ; DMT ; Female ; fingolimod ; Fingolimod Hydrochloride - administration & dosage ; Humans ; Immunosuppressive Agents - administration & dosage ; injections ; Injections - adverse effects ; Interferon beta-1a - administration & dosage ; Interferon beta-1b - administration & dosage ; interferons ; Male ; multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - psychology ; natalizumab ; Natalizumab - administration & dosage ; stress</subject><ispartof>Journal of comparative effectiveness research, 2017-07, Vol.6 (5), p.405-412</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383</citedby><cites>FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28699780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Hussain, Fawaz</creatorcontrib><creatorcontrib>Al-Salloum, Noura</creatorcontrib><creatorcontrib>Alazwary, Naael</creatorcontrib><creatorcontrib>Saeedi, Jameelah</creatorcontrib><creatorcontrib>Howaidi, Sara</creatorcontrib><creatorcontrib>Daif, Abdulkader</creatorcontrib><title>Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment.
Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital.
From 235 patients, 149 used interferons, 58 used fingolimod and 28 used natalizumab. Depression scores were similar among all demographic and drug groups. Interferons versus fingolimod anxiety scores were significantly different (p = 0.035). Stress scores were within normal limits.
Mild anxiety was higher among interferon users, which could be due to injection anxiety reasons.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>anxiety</subject><subject>Anxiety - etiology</subject><subject>Cross-Sectional Studies</subject><subject>DASS</subject><subject>depression</subject><subject>Depression - etiology</subject><subject>DMT</subject><subject>Female</subject><subject>fingolimod</subject><subject>Fingolimod Hydrochloride - administration & dosage</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>injections</subject><subject>Injections - adverse effects</subject><subject>Interferon beta-1a - administration & dosage</subject><subject>Interferon beta-1b - administration & dosage</subject><subject>interferons</subject><subject>Male</subject><subject>multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - psychology</subject><subject>natalizumab</subject><subject>Natalizumab - administration & dosage</subject><subject>stress</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kMtLxDAQh4MoKurRq-TowWoebZoeZX3Cghc9hzSdSqQvM6m4_70pu3ozl8kk3_xgPkLOObsWgpc3DkImGFcZY7rcI8eC5SJTksv9vzsrjsgZ4gdLR-m8KsQhORJaVVWp2TGZ7mAKgOjH4Yra4dtD3KTaUIzLM0X4guCjB6R-oP3cRT91QNF1EEb0SCebPoeIdEY_vCfoA1y0dWLSIM5Ix2A7msJs7BfulBy0tkM429UT8vZw_7p6ytYvj8-r23XmZC5j1ui6UE3V6sJVZd4wDjXTShXCigoUbxxzNWetVSBlDQ1LFrhwDKwTAExqeUIut7lTGD9nwGh6jw66zg4wzmh4xbXUOS9VQrMt6tJKGKA1U_C9DRvDmVk8m-TZLJ7N4jnxF7voue6h-aN_rSag2gLtHOek0SVDDsy2SxPe-QH-Cf8B9imPNA</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Al-Hussain, Fawaz</creator><creator>Al-Salloum, Noura</creator><creator>Alazwary, Naael</creator><creator>Saeedi, Jameelah</creator><creator>Howaidi, Sara</creator><creator>Daif, Abdulkader</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments</title><author>Al-Hussain, Fawaz ; Al-Salloum, Noura ; Alazwary, Naael ; Saeedi, Jameelah ; Howaidi, Sara ; Daif, Abdulkader</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>anxiety</topic><topic>Anxiety - etiology</topic><topic>Cross-Sectional Studies</topic><topic>DASS</topic><topic>depression</topic><topic>Depression - etiology</topic><topic>DMT</topic><topic>Female</topic><topic>fingolimod</topic><topic>Fingolimod Hydrochloride - administration & dosage</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>injections</topic><topic>Injections - adverse effects</topic><topic>Interferon beta-1a - administration & dosage</topic><topic>Interferon beta-1b - administration & dosage</topic><topic>interferons</topic><topic>Male</topic><topic>multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - psychology</topic><topic>natalizumab</topic><topic>Natalizumab - administration & dosage</topic><topic>stress</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Hussain, Fawaz</creatorcontrib><creatorcontrib>Al-Salloum, Noura</creatorcontrib><creatorcontrib>Alazwary, Naael</creatorcontrib><creatorcontrib>Saeedi, Jameelah</creatorcontrib><creatorcontrib>Howaidi, Sara</creatorcontrib><creatorcontrib>Daif, Abdulkader</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Hussain, Fawaz</au><au>Al-Salloum, Noura</au><au>Alazwary, Naael</au><au>Saeedi, Jameelah</au><au>Howaidi, Sara</au><au>Daif, Abdulkader</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>6</volume><issue>5</issue><spage>405</spage><epage>412</epage><pages>405-412</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment.
Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital.
From 235 patients, 149 used interferons, 58 used fingolimod and 28 used natalizumab. Depression scores were similar among all demographic and drug groups. Interferons versus fingolimod anxiety scores were significantly different (p = 0.035). Stress scores were within normal limits.
Mild anxiety was higher among interferon users, which could be due to injection anxiety reasons.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28699780</pmid><doi>10.2217/cer-2016-0087</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6305 |
| ispartof | Journal of comparative effectiveness research, 2017-07, Vol.6 (5), p.405-412 |
| issn | 2042-6305 2042-6313 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1918384176 |
| source | PubMed Central |
| subjects | Administration, Oral Adult anxiety Anxiety - etiology Cross-Sectional Studies DASS depression Depression - etiology DMT Female fingolimod Fingolimod Hydrochloride - administration & dosage Humans Immunosuppressive Agents - administration & dosage injections Injections - adverse effects Interferon beta-1a - administration & dosage Interferon beta-1b - administration & dosage interferons Male multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - psychology natalizumab Natalizumab - administration & dosage stress |
| title | Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A53%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depression,%20anxiety%20and%20stress%20severities%20in%20multiple%20sclerosis%20patients%20using%20injectable%20versus%20oral%20treatments&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Al-Hussain,%20Fawaz&rft.date=2017-07-01&rft.volume=6&rft.issue=5&rft.spage=405&rft.epage=412&rft.pages=405-412&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer-2016-0087&rft_dat=%3Cproquest_cross%3E1918384176%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c343t-d8b56d9f85c974d01eb086652a29e61dc0cb10fa6e33bed020112c0eac2ee0383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1918384176&rft_id=info:pmid/28699780&rfr_iscdi=true |